So far approved anti-GPCR drugs such as endothelin receptor blockers that block AT1R and ETAR are currently used as a treatment strategy, which is mainly based on treating clinical complications of SSc such as vasculopathy, PAH, and DU (90–92). This evidence concerns the gene AGTR1 and systemic sclerosis.